Baird Upgrades HealthEquity to Outperform, Raises Price Target to $87
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Mark Marcon has upgraded HealthEquity (NASDAQ:HQY) from Neutral to Outperform and raised the price target from $79 to $87.
September 21, 2023 | 9:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HealthEquity's stock rating has been upgraded to Outperform by Baird, with a raised price target of $87.
The upgrade from Neutral to Outperform by Baird indicates a positive outlook for HealthEquity. The raised price target from $79 to $87 suggests that the analyst expects the stock to outperform the market in the near future. This could potentially lead to an increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100